Drug Trial Radar · NCT00140218
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 2005
Primary completion
Jan 2007
Study completion Dec 2006
Sponsor
- Lead sponsor
- Bennett, James P., Jr., M.D., Ph.D.Individual
- Sponsor type
- Individual
- Collaborators
- University of Pittsburgh
- First posted
- Sep 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrateDrug
10 mg tid oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- ALS-FRSr score taken each month for 3 months during lead-in and for 6 months during treatmentTime frame: -3 -2 -1 0 1 2 3 4 5 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
David Lacomis MD
Pittsburgh, Pennsylvania
University of Virginia
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.